毒性薬物検査市場(検査タイプ:検査タイプ:インビトロ、インビボ、インシリコ;検査方法:質量分析イメージング、電子顕微鏡、蛍光標識、免疫組織化学、その他) - 世界の産業分析、規模、シェア、成長、動向、予測、2023-2031年Toxicology Drug Testing Market (Testing Type: In Vitro, In Vivo, In Silico; Testing Method: Mass Spectrometry Imaging, Electron Microscopy, Fluorescence Labeling, Immunohistochemistry, Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031 毒物検査市場 - レポートの範囲 TMRの調査レポート「毒性薬物検査の世界市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会につ... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー毒物検査市場 - レポートの範囲TMRの調査レポート「毒性薬物検査の世界市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2023年を基準年、2031年を予測年として、2017年から2031年までの毒性薬物検査の世界市場の収益を提供しています。また、2023年から2031年までの毒性薬物検査の世界市場の複合年間成長率(CAGR %)も掲載しています。 本レポートは広範な調査を経て作成されました。主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、毒性薬物検査市場を理解するために、主要企業の製品資料、年次報告書、プレスリリース、関連文書を参照した。 二次調査には、インターネット情報源、政府機関の統計データ、ウェブサイト、業界団体なども含まれる。アナリストは、世界の毒性薬物検査市場の様々な属性を調査するために、トップダウンアプローチとボトムアップアプローチの組み合わせを採用した。 本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、本レポートは、世界の毒物検査市場における競争ダイナミクスの変化に光を投げかけています。これらは、既存の市場プレイヤーだけでなく、世界の毒物検査市場への参入に関心のある企業にとっても貴重なツールとなります。 本レポートは、世界の毒物検査市場の競争状況について掘り下げています。世界の毒性薬物検査市場で事業を展開する主要企業が特定され、これらの各企業が様々な属性でプロファイリングされています。会社概要、財務状況、最近の動向、SWOTは、このレポートでプロファイリングされた世界の毒物検査市場のプレーヤーの属性です。 毒性薬物検査の世界市場レポートで回答された主な質問 - 予測期間中の全地域における毒物検査が生み出す売上高/収益は? - 世界の毒物検査市場におけるビジネスチャンスは? - 市場の主な促進要因、阻害要因、機会、脅威は何か? - 予測期間中に最も速いCAGRで拡大する地域市場はどこか? - 2031年に世界で最も高い収益を上げると予測されるセグメントは? - 予測期間中に最も高いCAGRで拡大すると予測されるセグメントは? - 世界市場で事業を展開する各企業の市場ポジションは? 毒性薬物検査市場 - 調査目的と調査アプローチ 毒性薬物検査の世界市場に関する包括的なレポートは、概要から始まり、調査範囲と目的が続きます。本レポートでは、本調査の目的、市場で事業を展開する主要ベンダーと販売業者、製品承認のための規制シナリオについて詳細に説明しています。 本レポートは、読みやすさを考慮し、各セクションを章ごとに分割したレイアウトになっています。本レポートは、グラフや表が適切に散りばめられた網羅的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴える。また、過去と予測期間末の主要セグメントの市場シェアを比較することもできる。 本レポートでは、世界の毒性薬物検査市場を製品、エンドユーザー、地域の観点から分析している。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントにおける市場シェアを掲載しています。このような貴重な洞察により、市場関係者は世界の毒性薬物検査市場への投資について、情報に基づいたビジネス上の意思決定を行うことができます。 目次1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Toxicology Drug Testing Market 4. Market Overview 4.1. Introduction 4.1.1. Segment Definition 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Toxicology Drug Testing Market Analysis and Forecast, 2017-2031 4.4.1. Market Revenue Projections (US$ Mn) 5. Key Insights 5.1. Technological Advancements 5.2. Regulatory Scenario by Region/Globally 5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact) 6. Global Toxicology Drug Testing Market Analysis and Forecast, by Testing Type 6.1. Introduction & Definition 6.2. Key Findings/Developments 6.3. Market Value Forecast, by Testing Type, 2017-2031 6.3.1. In Vitro 6.3.2. In Vivo 6.3.3. In Silico 6.4. Market Attractiveness Analysis, by Testing Type 7. Global Toxicology Drug Testing Market Analysis and Forecast, by Testing Method 7.1. Introduction & Definition 7.2. Key Findings/Developments 7.3. Market Value Forecast, by Testing Method, 2017-2031 7.3.1. Mass Spectrometry Imaging 7.3.2. Electron Microscopy 7.3.3. Fluorescence Labeling 7.3.4. Immunohistochemistry 7.3.5. Others 7.4. Market Attractiveness Analysis, by Testing Method 8. Global Toxicology Drug Testing Market Analysis and Forecast, by Application 8.1. Introduction & Definition 8.2. Key Findings/Developments 8.3. Market Value Forecast, by Application, 2017-2031 8.3.1. Drug Development 8.3.2. Substance Abuse and Addiction 8.3.3. Therapeutic Drug Monitoring 8.3.4. Others 8.4. Market Attractiveness Analysis, by Application 9. Global Toxicology Drug Testing Market Analysis and Forecast, by End-user 9.1. Introduction & Definition 9.2. Key Findings/Developments 9.3. Market Value Forecast, by End-user, 2017-2031 9.3.1. Cosmetics Industry 9.3.2. Healthcare Industry 9.3.2.1. Hospital and Clinics 9.3.2.2. Diagnostic Laboratories 9.3.2.3. Pharmaceutical & Biotechnology Companies 9.3.2.4. Others 9.3.3. Food Industry 9.3.4. Chemicals Industry 9.4. Market Attractiveness Analysis, by End-user 10. Global Toxicology Drug Testing Market Analysis and Forecast, by Region 10.1. Key Findings 10.2. Market Value Forecast, by Region, 2017-2031 10.2.1. North America 10.2.2. Europe 10.2.3. Asia Pacific 10.2.4. Latin America 10.2.5. Middle East & Africa 10.3. Market Attractiveness By Country/Region 11. North America Toxicology Drug Testing Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Testing Type, 2017-2031 11.2.1. In Vitro 11.2.2. In Vivo 11.2.3. In Silico 11.3. Market Value Forecast, by Testing Method, 2017-2031 11.3.1. Mass Spectrometry Imaging 11.3.2. Electron Microscopy 11.3.3. Fluorescence Labeling 11.3.4. Immunohistochemistry 11.3.5. Others 11.4. Market Value Forecast, by Application, 2017-2031 11.4.1. Drug Development 11.4.2. Substance Abuse and Addiction 11.4.3. Therapeutic Drug Monitoring 11.4.4. Others 11.5. Market Value Forecast, by End-user, 2017-2031 11.5.1. Cosmetics Industry 11.5.2. Healthcare Industry 11.5.2.1. Hospital and Clinics 11.5.2.2. Diagnostic Laboratories 11.5.2.3. Pharmaceutical & Biotechnology Companies 11.5.2.4. Others 11.5.3. Food Industry 11.5.4. Chemicals Industry 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031 11.6.1. U.S. 11.6.2. Canada 11.7. Market Attractiveness Analysis 11.7.1. By Testing Type 11.7.2. By Testing Method 11.7.3. By Application 11.7.4. By End-user 11.7.5. By Country/Sub-region 12. Europe Toxicology Drug Testing Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by Testing Type, 2017-2031 12.2.1. In Vitro 12.2.2. In Vivo 12.2.3. In Silico 12.3. Market Value Forecast, by Testing Method, 2017-2031 12.3.1. Mass Spectrometry Imaging 12.3.2. Electron Microscopy 12.3.3. Fluorescence Labeling 12.3.4. Immunohistochemistry 12.3.5. Others 12.4. Market Value Forecast, by Application, 2017-2031 12.4.1. Drug Development 12.4.2. Substance Abuse and Addiction 12.4.3. Therapeutic Drug Monitoring 12.4.4. Others 12.5. Market Value Forecast, by End-user, 2017-2031 12.5.1. Cosmetics Industry 12.5.2. Healthcare Industry 12.5.2.1. Hospital and Clinics 12.5.2.2. Diagnostic Laboratories 12.5.2.3. Pharmaceutical & Biotechnology Companies 12.5.2.4. Others 12.5.3. Food Industry 12.5.4. Chemicals Industry 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031 12.6.1. Germany 12.6.2. U.K. 12.6.3. France 12.6.4. Italy 12.6.5. Spain 12.6.6. Rest of Europe 12.7. Market Attractiveness Analysis 12.7.1. By Testing Type 12.7.2. By Testing Method 12.7.3. By Application 12.7.4. By End-user 12.7.5. By Country/Sub-region 13. Asia Pacific Toxicology Drug Testing Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Testing Type, 2017-2031 13.2.1. In Vitro 13.2.2. In Vivo 13.2.3. In Silico 13.3. Market Value Forecast, by Testing Method, 2017-2031 13.3.1. Mass Spectrometry Imaging 13.3.2. Electron Microscopy 13.3.3. Fluorescence Labeling 13.3.4. Immunohistochemistry 13.3.5. Others 13.4. Market Value Forecast, by Application, 2017-2031 13.4.1. Drug Development 13.4.2. Substance Abuse and Addiction 13.4.3. Therapeutic Drug Monitoring 13.4.4. Others 13.5. Market Value Forecast, by End-user, 2017-2031 13.5.1. Cosmetics Industry 13.5.2. Healthcare Industry 13.5.2.1. Hospital and Clinics 13.5.2.2. Diagnostic Laboratories 13.5.2.3. Pharmaceutical & Biotechnology Companies 13.5.2.4. Others 13.5.3. Food Industry 13.5.4. Chemicals Industry 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031 13.6.1. China 13.6.2. Japan 13.6.3. India 13.6.4. Australia & New Zealand 13.6.5. Rest of Asia Pacific 13.7. Market Attractiveness Analysis 13.7.1. By Testing Type 13.7.2. By Testing Method 13.7.3. By Application 13.7.4. By End-user 13.7.5. By Country/Sub-region 14. Latin America Toxicology Drug Testing Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Testing Type, 2017-2031 14.2.1. In Vitro 14.2.2. In Vivo 14.2.3. In Silico 14.3. Market Value Forecast, by Testing Method, 2017-2031 14.3.1. Mass Spectrometry Imaging 14.3.2. Electron Microscopy 14.3.3. Fluorescence Labeling 14.3.4. Immunohistochemistry 14.3.5. Others 14.4. Market Value Forecast, by Application, 2017-2031 14.4.1. Drug Development 14.4.2. Substance Abuse and Addiction 14.4.3. Therapeutic Drug Monitoring 14.4.4. Others 14.5. Market Value Forecast, by End-user, 2017-2031 14.5.1. Cosmetics Industry 14.5.2. Healthcare Industry 14.5.2.1. Hospital and Clinics 14.5.2.2. Diagnostic Laboratories 14.5.2.3. Pharmaceutical & Biotechnology Companies 14.5.2.4. Others 14.5.3. Food Industry 14.5.4. Chemicals Industry 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031 14.6.1. Brazil 14.6.2. Mexico 14.6.3. Rest of Latin America 14.7. Market Attractiveness Analysis 14.7.1. By Testing Type 14.7.2. By Testing Method 14.7.3. By Application 14.7.4. By End-user 14.7.5. By Country/Sub-region 15. Middle East & Africa Toxicology Drug Testing Market Analysis and Forecast 15.1. Introduction 15.1.1. Key Findings 15.2. Market Value Forecast, by Testing Type, 2017-2031 15.2.1. In Vitro 15.2.2. In Vivo 15.2.3. In Silico 15.3. Market Value Forecast, by Testing Method, 2017-2031 15.3.1. Mass Spectrometry Imaging 15.3.2. Electron Microscopy 15.3.3. Fluorescence Labeling 15.3.4. Immunohistochemistry 15.3.5. Others 15.4. Market Value Forecast, by End-user, 2017-2031 15.4.1. Drug Development 15.4.2. Substance Abuse and Addiction 15.4.3. Therapeutic Drug Monitoring 15.4.4. Others 15.5. Market Value Forecast, by Application, 2017-2031 15.5.1. Cosmetics Industry 15.5.2. Healthcare Industry 15.5.2.1. Hospital and Clinics 15.5.2.2. Diagnostic Laboratories 15.5.2.3. Pharmaceutical & Biotechnology Companies 15.5.2.4. Others 15.5.3. Food Industry 15.5.4. Chemicals Industry 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031 15.6.1. GCC Countries 15.6.2. South Africa 15.6.3. Rest of Middle East & Africa 15.7. Market Attractiveness Analysis 15.7.1. By Testing Type 15.7.2. By Testing Method 15.7.3. By Application 15.7.4. By End-user 15.7.5. By Country/Sub-region 16. Competition Landscape 16.1. Market Player - Competition Matrix (By Tier and Size of Companies) 16.2. Market Share Analysis, by Company (2022) 16.3. Company Profiles 16.3.1. TDAL Labs 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.1.2. Product Portfolio 16.3.1.3. Financial Overview 16.3.1.4. SWOT Analysis 16.3.1.5. Strategic Overview 16.3.2. Thermo Fisher Scientific Inc. 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.2.2. Product Portfolio 16.3.2.3. Financial Overview 16.3.2.4. SWOT Analysis 16.3.2.5. Strategic Overview 16.3.3. Abbott 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.3.2. Product Portfolio 16.3.3.3. Financial Overview 16.3.3.4. SWOT Analysis 16.3.3.5. Strategic Overview 16.3.4. Icahn School of Medicine at Mount Sinai 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.4.2. Product Portfolio 16.3.4.3. Financial Overview 16.3.4.4. SWOT Analysis 16.3.4.5. Strategic Overview 16.3.5. Clinisys, Inc. 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.5.2. Product Portfolio 16.3.5.3. Financial Overview 16.3.5.4. SWOT Analysis 16.3.5.5. Strategic Overview 16.3.6. Laboratory Corporation of America Holdings 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.6.2. Product Portfolio 16.3.6.3. Financial Overview 16.3.6.4. SWOT Analysis 16.3.6.5. Strategic Overview 16.3.7. SLUCARE 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.7.2. Product Portfolio 16.3.7.3. Financial Overview 16.3.7.4. SWOT Analysis 16.3.7.5. Strategic Overview 16.3.8. Keystone Lab 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.8.2. Product Portfolio 16.3.8.3. Financial Overview 16.3.8.4. SWOT Analysis 16.3.8.5. Strategic Overview 16.3.9. Shimadzu Scientific Instruments 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.9.2. Product Portfolio 16.3.9.3. Financial Overview 16.3.9.4. SWOT Analysis 16.3.9.5. Strategic Overview 16.3.10. Ganesh Diagnostic & Imaging Centre Pvt. Ltd. 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.10.2. Product Portfolio 16.3.10.3. Financial Overview 16.3.10.4. SWOT Analysis 16.3.10.5. Strategic Overview 16.3.11. Other Players 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.11.2. Product Portfolio 16.3.11.3. Financial Overview 16.3.11.4. SWOT Analysis 16.3.11.5. Strategic Overview
SummaryToxicology Drug Testing Market – Scope of Report Table of Contents1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Toxicology Drug Testing Market 4. Market Overview 4.1. Introduction 4.1.1. Segment Definition 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Toxicology Drug Testing Market Analysis and Forecast, 2017-2031 4.4.1. Market Revenue Projections (US$ Mn) 5. Key Insights 5.1. Technological Advancements 5.2. Regulatory Scenario by Region/Globally 5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact) 6. Global Toxicology Drug Testing Market Analysis and Forecast, by Testing Type 6.1. Introduction & Definition 6.2. Key Findings/Developments 6.3. Market Value Forecast, by Testing Type, 2017-2031 6.3.1. In Vitro 6.3.2. In Vivo 6.3.3. In Silico 6.4. Market Attractiveness Analysis, by Testing Type 7. Global Toxicology Drug Testing Market Analysis and Forecast, by Testing Method 7.1. Introduction & Definition 7.2. Key Findings/Developments 7.3. Market Value Forecast, by Testing Method, 2017-2031 7.3.1. Mass Spectrometry Imaging 7.3.2. Electron Microscopy 7.3.3. Fluorescence Labeling 7.3.4. Immunohistochemistry 7.3.5. Others 7.4. Market Attractiveness Analysis, by Testing Method 8. Global Toxicology Drug Testing Market Analysis and Forecast, by Application 8.1. Introduction & Definition 8.2. Key Findings/Developments 8.3. Market Value Forecast, by Application, 2017-2031 8.3.1. Drug Development 8.3.2. Substance Abuse and Addiction 8.3.3. Therapeutic Drug Monitoring 8.3.4. Others 8.4. Market Attractiveness Analysis, by Application 9. Global Toxicology Drug Testing Market Analysis and Forecast, by End-user 9.1. Introduction & Definition 9.2. Key Findings/Developments 9.3. Market Value Forecast, by End-user, 2017-2031 9.3.1. Cosmetics Industry 9.3.2. Healthcare Industry 9.3.2.1. Hospital and Clinics 9.3.2.2. Diagnostic Laboratories 9.3.2.3. Pharmaceutical & Biotechnology Companies 9.3.2.4. Others 9.3.3. Food Industry 9.3.4. Chemicals Industry 9.4. Market Attractiveness Analysis, by End-user 10. Global Toxicology Drug Testing Market Analysis and Forecast, by Region 10.1. Key Findings 10.2. Market Value Forecast, by Region, 2017-2031 10.2.1. North America 10.2.2. Europe 10.2.3. Asia Pacific 10.2.4. Latin America 10.2.5. Middle East & Africa 10.3. Market Attractiveness By Country/Region 11. North America Toxicology Drug Testing Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Testing Type, 2017-2031 11.2.1. In Vitro 11.2.2. In Vivo 11.2.3. In Silico 11.3. Market Value Forecast, by Testing Method, 2017-2031 11.3.1. Mass Spectrometry Imaging 11.3.2. Electron Microscopy 11.3.3. Fluorescence Labeling 11.3.4. Immunohistochemistry 11.3.5. Others 11.4. Market Value Forecast, by Application, 2017-2031 11.4.1. Drug Development 11.4.2. Substance Abuse and Addiction 11.4.3. Therapeutic Drug Monitoring 11.4.4. Others 11.5. Market Value Forecast, by End-user, 2017-2031 11.5.1. Cosmetics Industry 11.5.2. Healthcare Industry 11.5.2.1. Hospital and Clinics 11.5.2.2. Diagnostic Laboratories 11.5.2.3. Pharmaceutical & Biotechnology Companies 11.5.2.4. Others 11.5.3. Food Industry 11.5.4. Chemicals Industry 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031 11.6.1. U.S. 11.6.2. Canada 11.7. Market Attractiveness Analysis 11.7.1. By Testing Type 11.7.2. By Testing Method 11.7.3. By Application 11.7.4. By End-user 11.7.5. By Country/Sub-region 12. Europe Toxicology Drug Testing Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by Testing Type, 2017-2031 12.2.1. In Vitro 12.2.2. In Vivo 12.2.3. In Silico 12.3. Market Value Forecast, by Testing Method, 2017-2031 12.3.1. Mass Spectrometry Imaging 12.3.2. Electron Microscopy 12.3.3. Fluorescence Labeling 12.3.4. Immunohistochemistry 12.3.5. Others 12.4. Market Value Forecast, by Application, 2017-2031 12.4.1. Drug Development 12.4.2. Substance Abuse and Addiction 12.4.3. Therapeutic Drug Monitoring 12.4.4. Others 12.5. Market Value Forecast, by End-user, 2017-2031 12.5.1. Cosmetics Industry 12.5.2. Healthcare Industry 12.5.2.1. Hospital and Clinics 12.5.2.2. Diagnostic Laboratories 12.5.2.3. Pharmaceutical & Biotechnology Companies 12.5.2.4. Others 12.5.3. Food Industry 12.5.4. Chemicals Industry 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031 12.6.1. Germany 12.6.2. U.K. 12.6.3. France 12.6.4. Italy 12.6.5. Spain 12.6.6. Rest of Europe 12.7. Market Attractiveness Analysis 12.7.1. By Testing Type 12.7.2. By Testing Method 12.7.3. By Application 12.7.4. By End-user 12.7.5. By Country/Sub-region 13. Asia Pacific Toxicology Drug Testing Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Testing Type, 2017-2031 13.2.1. In Vitro 13.2.2. In Vivo 13.2.3. In Silico 13.3. Market Value Forecast, by Testing Method, 2017-2031 13.3.1. Mass Spectrometry Imaging 13.3.2. Electron Microscopy 13.3.3. Fluorescence Labeling 13.3.4. Immunohistochemistry 13.3.5. Others 13.4. Market Value Forecast, by Application, 2017-2031 13.4.1. Drug Development 13.4.2. Substance Abuse and Addiction 13.4.3. Therapeutic Drug Monitoring 13.4.4. Others 13.5. Market Value Forecast, by End-user, 2017-2031 13.5.1. Cosmetics Industry 13.5.2. Healthcare Industry 13.5.2.1. Hospital and Clinics 13.5.2.2. Diagnostic Laboratories 13.5.2.3. Pharmaceutical & Biotechnology Companies 13.5.2.4. Others 13.5.3. Food Industry 13.5.4. Chemicals Industry 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031 13.6.1. China 13.6.2. Japan 13.6.3. India 13.6.4. Australia & New Zealand 13.6.5. Rest of Asia Pacific 13.7. Market Attractiveness Analysis 13.7.1. By Testing Type 13.7.2. By Testing Method 13.7.3. By Application 13.7.4. By End-user 13.7.5. By Country/Sub-region 14. Latin America Toxicology Drug Testing Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Testing Type, 2017-2031 14.2.1. In Vitro 14.2.2. In Vivo 14.2.3. In Silico 14.3. Market Value Forecast, by Testing Method, 2017-2031 14.3.1. Mass Spectrometry Imaging 14.3.2. Electron Microscopy 14.3.3. Fluorescence Labeling 14.3.4. Immunohistochemistry 14.3.5. Others 14.4. Market Value Forecast, by Application, 2017-2031 14.4.1. Drug Development 14.4.2. Substance Abuse and Addiction 14.4.3. Therapeutic Drug Monitoring 14.4.4. Others 14.5. Market Value Forecast, by End-user, 2017-2031 14.5.1. Cosmetics Industry 14.5.2. Healthcare Industry 14.5.2.1. Hospital and Clinics 14.5.2.2. Diagnostic Laboratories 14.5.2.3. Pharmaceutical & Biotechnology Companies 14.5.2.4. Others 14.5.3. Food Industry 14.5.4. Chemicals Industry 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031 14.6.1. Brazil 14.6.2. Mexico 14.6.3. Rest of Latin America 14.7. Market Attractiveness Analysis 14.7.1. By Testing Type 14.7.2. By Testing Method 14.7.3. By Application 14.7.4. By End-user 14.7.5. By Country/Sub-region 15. Middle East & Africa Toxicology Drug Testing Market Analysis and Forecast 15.1. Introduction 15.1.1. Key Findings 15.2. Market Value Forecast, by Testing Type, 2017-2031 15.2.1. In Vitro 15.2.2. In Vivo 15.2.3. In Silico 15.3. Market Value Forecast, by Testing Method, 2017-2031 15.3.1. Mass Spectrometry Imaging 15.3.2. Electron Microscopy 15.3.3. Fluorescence Labeling 15.3.4. Immunohistochemistry 15.3.5. Others 15.4. Market Value Forecast, by End-user, 2017-2031 15.4.1. Drug Development 15.4.2. Substance Abuse and Addiction 15.4.3. Therapeutic Drug Monitoring 15.4.4. Others 15.5. Market Value Forecast, by Application, 2017-2031 15.5.1. Cosmetics Industry 15.5.2. Healthcare Industry 15.5.2.1. Hospital and Clinics 15.5.2.2. Diagnostic Laboratories 15.5.2.3. Pharmaceutical & Biotechnology Companies 15.5.2.4. Others 15.5.3. Food Industry 15.5.4. Chemicals Industry 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031 15.6.1. GCC Countries 15.6.2. South Africa 15.6.3. Rest of Middle East & Africa 15.7. Market Attractiveness Analysis 15.7.1. By Testing Type 15.7.2. By Testing Method 15.7.3. By Application 15.7.4. By End-user 15.7.5. By Country/Sub-region 16. Competition Landscape 16.1. Market Player - Competition Matrix (By Tier and Size of Companies) 16.2. Market Share Analysis, by Company (2022) 16.3. Company Profiles 16.3.1. TDAL Labs 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.1.2. Product Portfolio 16.3.1.3. Financial Overview 16.3.1.4. SWOT Analysis 16.3.1.5. Strategic Overview 16.3.2. Thermo Fisher Scientific Inc. 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.2.2. Product Portfolio 16.3.2.3. Financial Overview 16.3.2.4. SWOT Analysis 16.3.2.5. Strategic Overview 16.3.3. Abbott 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.3.2. Product Portfolio 16.3.3.3. Financial Overview 16.3.3.4. SWOT Analysis 16.3.3.5. Strategic Overview 16.3.4. Icahn School of Medicine at Mount Sinai 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.4.2. Product Portfolio 16.3.4.3. Financial Overview 16.3.4.4. SWOT Analysis 16.3.4.5. Strategic Overview 16.3.5. Clinisys, Inc. 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.5.2. Product Portfolio 16.3.5.3. Financial Overview 16.3.5.4. SWOT Analysis 16.3.5.5. Strategic Overview 16.3.6. Laboratory Corporation of America Holdings 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.6.2. Product Portfolio 16.3.6.3. Financial Overview 16.3.6.4. SWOT Analysis 16.3.6.5. Strategic Overview 16.3.7. SLUCARE 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.7.2. Product Portfolio 16.3.7.3. Financial Overview 16.3.7.4. SWOT Analysis 16.3.7.5. Strategic Overview 16.3.8. Keystone Lab 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.8.2. Product Portfolio 16.3.8.3. Financial Overview 16.3.8.4. SWOT Analysis 16.3.8.5. Strategic Overview 16.3.9. Shimadzu Scientific Instruments 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.9.2. Product Portfolio 16.3.9.3. Financial Overview 16.3.9.4. SWOT Analysis 16.3.9.5. Strategic Overview 16.3.10. Ganesh Diagnostic & Imaging Centre Pvt. Ltd. 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.10.2. Product Portfolio 16.3.10.3. Financial Overview 16.3.10.4. SWOT Analysis 16.3.10.5. Strategic Overview 16.3.11. Other Players 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.11.2. Product Portfolio 16.3.11.3. Financial Overview 16.3.11.4. SWOT Analysis 16.3.11.5. Strategic Overview
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
Transparency Market Research社の医療分野での最新刊レポート
本レポートと同じKEY WORD(drug)の最新刊レポート
よくあるご質問Transparency Market Research社はどのような調査会社ですか?トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/25 10:26 155.25 円 163.23 円 198.36 円 |